Obagi Nu-Derm Clear Rx: keep the prescription record separate from Clear Fx

The official page’s address contains the word “serum,” but its visible title describes a dark-spot lightener and corrector cream. The page identifies Obagi Nu-Derm Clear and prescription hydroquinone 4%. The product description, rather than a word in a web address, is the relevant identity record. Obagi prescription page

It also lists inactive ingredients, including glycerin, ascorbic acid, lactic acid and sodium metabisulfite among others. These disclosures are useful when asking about the actual product. They do not establish that an individual container has been inspected or that a particular patient can use it without a problem.

Obagi specifically warns that sodium metabisulfite may cause allergic-type reactions, including serious reactions in susceptible people. That is a formulation-specific concern to discuss with a professional. The ingredient list should not be reduced to hydroquinone alone, but it also cannot be used here to diagnose a sulfite allergy or identify the cause of someone’s symptoms. Ingredient and safety record

The page includes pregnancy and nursing uncertainty as well. This publication does not resolve those questions from age, past experience or a product comparison. An actual professional assessment requires relevant history and the proposed preparation, not reassurance inferred from a familiar brand name.

The separate Clear Fx page advertises a skin-brightening cream with arbutin and antioxidants and displays a regular price of $125. Its published ingredient list does not identify hydroquinone. The page’s retail shipping and return statements belong to that offering; they cannot be copied into a quote for Clear Rx. Clear Fx page

The distinction is more than a missing letter on a shopping list. A review of hydroquinone cannot use an arbutin product’s price, reviews or purchase button as evidence for the prescription cream. The percentage guide similarly explains why a familiar category label does not settle exact preparation or equivalence.

Obagi directs readers to a healthcare provider or its physician locator for the prescription product. That is a route for obtaining professional information, not evidence that a particular clinic currently stocks the product, accepts a patient or quotes one standard price. We did not call practices or inspect inventories. Professional access description

A meaningful quote would identify the exact Rx product, supplied amount, assessment charges and any dispensing or shipping costs. The manufacturer page alone does not establish those answers. The CoreAge review has a different kind of offer record, but its published plans do not make these unknown Obagi costs directly comparable.

The official page clearly describes a prescription requirement. That should not be expanded into a claim of FDA approval. FDA’s posted hydroquinone communication identifies Tri-Luma as the approved hydroquinone-containing drug and specifies its limited facial melasma use. A different named product does not acquire that status because it contains the same ingredient. FDA hydroquinone record

The approval and compounding guide also separates a commercially manufactured prescription record from a provider’s compounded offer. This review does not label Obagi Clear as a custom compound merely because it is not established here as an approved product, nor does it make a legal determination about a future prescription or sale.

Obagi markets the cream for several types of discoloration. Those descriptions do not mean a reader’s mark has been diagnosed or that all pigment concerns call for the same treatment. AAD explains that melasma may resemble other skin conditions and that a dermatologist can use examination, additional viewing or a biopsy when needed to clarify the problem. AAD diagnostic context

That is the starting point of the dark-spot assessment article. A familiar percentage is not an answer to an uncertain diagnosis. A professional may need information beyond what is available in a photograph or online shopping description.

FDA reports hydroquinone-associated rashes, swelling and ochronosis, which can involve lasting discoloration. Those reports should not be treated as a measured risk estimate for a particular Obagi prescription. They also rule out a casual assumption that new darkening simply proves the cream is working. FDA safety communication

The follow-up discussion asks who assesses an unwanted change and which professional can clarify the intended care plan. It does not set a course or tell the reader how to alter treatment. What this review confirms is the public identity and listed formulation—not personal suitability, an available container or the outcome of using one.